Achillion Pharmaceuticals (NASDAQ:ACHN) Stock Rating Lowered by ValuEngine

ValuEngine downgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a strong sell rating in a report published on Thursday, ValuEngine reports.

Other equities analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a hold rating to a sell rating and set a $4.75 target price on the stock. in a research report on Tuesday, August 27th. BidaskClub upgraded shares of Achillion Pharmaceuticals from a strong sell rating to a sell rating in a research report on Saturday, October 5th. Four analysts have rated the stock with a sell rating and one has issued a buy rating to the stock. The company has a consensus rating of Sell and an average price target of $3.63.

Shares of ACHN traded up $0.04 during mid-day trading on Thursday, reaching $3.68. 328,027 shares of the company’s stock were exchanged, compared to its average volume of 1,701,084. The stock has a market capitalization of $505.68 million, a PE ratio of -7.21 and a beta of 1.57. The business’s fifty day simple moving average is $4.00 and its 200-day simple moving average is $3.40. Achillion Pharmaceuticals has a 52-week low of $1.29 and a 52-week high of $5.03.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14). As a group, equities analysts forecast that Achillion Pharmaceuticals will post -0.59 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Rock Springs Capital Management LP grew its position in shares of Achillion Pharmaceuticals by 9.3% during the second quarter. Rock Springs Capital Management LP now owns 2,950,000 shares of the biopharmaceutical company’s stock worth $7,906,000 after acquiring an additional 250,000 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Achillion Pharmaceuticals by 22.2% during the second quarter. JPMorgan Chase & Co. now owns 689,569 shares of the biopharmaceutical company’s stock worth $1,835,000 after purchasing an additional 125,310 shares during the period. DekaBank Deutsche Girozentrale lifted its holdings in shares of Achillion Pharmaceuticals by 63.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 108,600 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 42,300 shares during the period. Mak Capital One LLC lifted its holdings in shares of Achillion Pharmaceuticals by 33.5% during the first quarter. Mak Capital One LLC now owns 6,929,653 shares of the biopharmaceutical company’s stock worth $20,512,000 after purchasing an additional 1,738,053 shares during the period. Finally, Swiss National Bank lifted its holdings in shares of Achillion Pharmaceuticals by 21.3% during the second quarter. Swiss National Bank now owns 245,100 shares of the biopharmaceutical company’s stock worth $657,000 after purchasing an additional 43,000 shares during the period. Institutional investors and hedge funds own 78.57% of the company’s stock.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Featured Story: Understanding the different types of bonds

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.